Innospec (IOSP) Cash & Equivalents (2010 - 2026)

Innospec has disclosed Cash & Equivalents across 17 years of filings, most recently posting $289.1 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $289.1 million, down 3.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $289.1 million (down 3.57% YoY), and the FY2025 annual result was $292.5 million, up 1.14% from the prior year.
• Cash & Equivalents came in at $289.1 million for Q1 2026 at Innospec, down from $292.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $303.8 million in Q3 2024 to a low of $71.4 million in Q2 2022.
• The 5-year median for Cash & Equivalents is $240.2 million (2024), against an average of $215.9 million.
• Across the five-year window, Cash & Equivalents retreated 24.36% in 2022 and jumped 132.35% in 2023, its largest moves.
• Innospec's Cash & Equivalents stood at $147.1 million in 2022, then soared by 38.48% to $203.7 million in 2023, then surged by 41.97% to $289.2 million in 2024, then increased by 1.14% to $292.5 million in 2025, then declined by 1.16% to $289.1 million in 2026.
• The last three Cash & Equivalents figures came in at $289.1 million (Q1 2026), $292.5 million (Q4 2025), and $270.8 million (Q3 2025), per Business Quant data.